Anticoagulation for ST-segment elevation myocardial infarction

Circulation

Volumn 119, Issue 9, 2009, Pages 1186-1188

  Eikelboom, John W ^a,b   Weitz, Jeffrey I ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Anticoagulants; Editorials; Heparin; Myocardial infarction

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8; ENOXAPARIN; FACTOR IXA DIRECTED APTAMER; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT;

ANTICOAGULATION; BLEEDING; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HEART REINFARCTION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECURRENCE RISK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; CORONARY ARTERY THROMBOSIS; ELECTROCARDIOGRAPHY; NOTE;

ANTICOAGULANTS; CORONARY THROMBOSIS; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION;

EID: 63649129783     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.845552     Document Type: Editorial

References (20)

1. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996;313:652-659.
2. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation. 2005;112:3855-3867.
3. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354: 1477-1488.
4. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519-1530.
5. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Menran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.
6. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994-3018.
7. Cheng S, Morrow DA, Sloan S, Antman EM, Sabatine MS. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation. 2009; 119: 1195-1202.
8. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
9. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation. 2008;117:296-329.
10. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997;157:2562-2568.
11. Anand SS, Bates S, Ginsberg JS, Levine M, Buller H, Prins M, Haley S, Kearon C, Hirsh J, Gent M. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med. 1999;159:2029-2032.
12. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003;107:2884-2888.
13. Granger CB, Hirsch J, Califf RM. Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation. 1996;93: 870-878.
14. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006;96:547-552.
15. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998; 122: 782-798.
16. van den Besselaar AM, Sturk A, Reijnierse GL. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges. Thromb Res. 2002;107:235-240.
17. Rapaport SI, Vermylen J, Hoylaerts M, Saito H, Hirsh J, Bates S, Dahlback B, Poller L. The multiple faces of the partial thromboplastin time APTT. J Thromb Haemost. 2004;2:2250-2259.
18. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med. 1993; 119: 874-881.
19. Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, Zhu J, Liu L. Effects of reviparin, a low-molecular-weight heparin, on mortality, rein- farction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA. 2005;293:427-435.
20. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Phase lb randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008;117:2865-2874.